CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. SBUX
8. AXP
9. ZETA
10. TMUS

Go back to CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

CRISPR Therapeutics (CRSP) PT Lowered to $59 at Barclays

August 6, 2024 3:02 AM EDT

Barclays analyst Gena Wang lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $59.00 (from $67.00) while maintaining a Equalweight rating.... More

CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c

August 5, 2024 4:04 PM EDT

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

... More

Rodman & Renshaw Starts CRISPR Therapeutics (CRSP) at Buy

August 2, 2024 6:44 AM EDT

Rodman & Renshaw analyst Tony Butler initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $90.00.


For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.


Shares of CRISPR Therapeutics closed at $54.85 yesterday.

... More